Endometriosis Market : Size, Capacity and Forecast Analysis 2018 to 2025

1
Global Endometriosis Market

• Size by Drug Type (NSAIDs, Gonadotropins
  Releasing Hormone Agonists, Progestin, and Oral
  Contraceptive Pills) by Region and Forecast 2018
  to 2025

Single Use License US 4150
Request Sample
2
Global Endometriosis Market Size, Share , Price
Analysis Report 2025

• Adroit Market Research launched a study titled,
  Global Endometriosis Market Size by Drug Type
  (NSAIDs, Gonadotropins Releasing Hormone
  Agonists, Progestin, and Oral Contraceptive
  Pills), by Region and Forecast 2018 to 2025. The
  study covers the global endometriosis drugs
  market value for a period ranging in between 2015
  to 2025, where 2015 to 2017 imply the historical
  value with forecast between 2018 and 2025. The
  global endometriosis treatment market report also
  includes qualitative insights of the market such
  as pipeline analysis, porters five forces
  analysis, drivers and restraints. Trends for the
  global endometriosis diagnosis market have also
  been covered in this study.
• The global endometriosis market size is expected
  to reach USD 2.29 billion by 2025. The increasing
  female population within the age group of 15-49
  years across developed as well as developing
  economies is expected to fuel the endometriosis
  drugs market growth over the forecast period.
  High prevalence of endometriosis among the female
  population of reproductive age is expected to
  drive the endometriosis treatment market demand
  in the coming years.
• Symptoms such as pain instantly before and during
  a period, ovulation pain, and irregular or heavy
  bleeding during periods have resulted in a
  significant decrease in working female
  population. Productivity loss of approximately 11
  hours per week has been observed in diagnosed
  patients. High prevalence, undefined etiology,
  and high productivity loss are major factors
  resulting in a large number of research
  institutes and drug manufacturers engaging in
  research for optimum diagnosis and treatment for
  the condition.
• Drug classes namely NSAIDs, gonadotropins
  releasing hormone agonists, oral contraceptives,
  and progestin therapy are widely used for pain
  management post-diagnosis. Nonsteroidal
  anti-inflammatory drug segment dominated the
  global endometriosis market by contributing major
  market share and is expected to maintain its
  dominance over the forecast period contributing
  to40.6 of the revenues by 2025.

3
Global Endometriosis Market Size, Share , Price
Analysis Report 2025

• Presence of a large number of companies actively
  involved in clinical trials for disease
  management is expected to change the current
  market dynamics in the coming years. In April
  2018, Bayer in collaboration with Evotec
  announced phase I trials of new small molecules
  for the treatment of endometriosis. Furthermore,
  as of January 2019, 24 studies are under phase
  III and are expected to show positive results,
  which will provide opportunities for the further
  development of the global endometriosis treatment
  market.
• North America dominated the global endometriosis
  market in 2017 and is expected to grow at a
  lucrative CAGR by 2025. High prevalence within
  the U.S., coupled with the presence of a large
  number of working female population has created a
  potential market for drug manufacturers.
  According to ENDOFOUND.ORG, 7 million women in
  the U.S. have endometriosis. On the other hand,
  the financial burden of USD 87 billion has been
  estimated within the U.S. every year for medical
  costs and reduced work productivity. Such factors
  are expected to support regional growth over the
  forecast period.
• The global endometriosis market is marked by the
  presence of well-established drug manufacturers
  such as AstraZeneca, Bayer AG, Neurocrine
  Biosciences, Inc., Meditrina Pharmaceuticals Inc.
  and many more. Major players within the market
  are actively involved in clinical trials to
  develop novel treatment and diagnosis options to
  reduce the financial burden of the medical
  condition.
• Browse the complete report on _at_
  https//www.adroitmarketresearch.com/industry-repo
  rts/endometriosis-market

4
Key segments of the global endometriosis market

• Drug Type Overview, 2015-2025 (USD million)
• NSAIDs
• Gonadotropins Releasing Hormone agonists
• Progestin
• Oral contraceptive pills
• Regional Overview, 2015-2025 (USD million)
• North America
• Europe
• Asia Pacific
• Rest of the World
• Purchase a single user copy of the global
  endometriosis market report_at_ https//www.adroitmar
  ketresearch.com/researchreport/purchase/784

5
About Us

• Adroit Market Research is an India-based business
  analytics and consulting company. Our target
  audience is a wide range of corporations,
  manufacturing companies, product/technology
  development institutions and industry
  associations that require understanding of a
  markets size, key trends, participants and
  future outlook of an industry. We intend to
  become our clients knowledge partner and provide
  them with valuable market insights to help create
  opportunities that increase their revenues. We
  follow a code Explore, Learn and Transform. At
  our core, we are curious people who love to
  identify and understand industry patterns, create
  an insightful study around our findings and churn
  out money-making roadmaps. Our analysts have
  tracked high growth markets in chemicals
  materials, healthcare pharmaceuticals,
  semiconductor electronics, energy power, food
  retail, consumer goods, technology, and
  machinery equipment sectors across the world to
  identify new opportunities, potential customers,
  prepare go-to-market (GTM) strategies, identify
  segments for revenue growth for companies, and
  many more.

• US Headquarters3131 McKinney Ave Ste 600
  Dallas, TX 75204 ,U.S.A 

• Phone [phone]
• Email sales_at_adroitmarketresearch.com